{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:44:14Z","timestamp":1783943054022,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.japh.2020.02.025","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T16:55:20Z","timestamp":1585241720000},"page":"729-733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost comparison of AUC:MIC\u2013 versus trough-based vancomycin monitoring for MRSA bacteremia"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4416-8035","authenticated-orcid":false,"given":"Mario V.","family":"Beccari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0365-6713","authenticated-orcid":false,"given":"Robert W.","family":"Seabury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-6366","authenticated-orcid":false,"given":"Bryan T.","family":"Mogle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-096X","authenticated-orcid":false,"given":"Wesley D.","family":"Kufel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.japh.2020.02.025_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jcpt.12323","article-title":"Vancomycin serum trough concentration vs. clinical outcome in patients with gram-positive infection: a retrospective analysis","volume":"40","author":"Cao","year":"2015","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.japh.2020.02.025_bib2","doi-asserted-by":"crossref","unstructured":"Rodvold KA. 60 plus years later and we are still trying to learn how to dose vancomycin. Clin Infect Dis. [e-pub ahead of print] https:\/\/doi.org\/10.1093\/cid\/ciz467. Accessed June 18, 2019.","DOI":"10.1093\/cid\/ciz467"},{"issue":"Suppl 1","key":"10.1016\/j.japh.2020.02.025_bib3","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"13","key":"10.1016\/j.japh.2020.02.025_bib4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.japh.2020.02.025_bib5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.japh.2020.02.025_bib6","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/AAC.01485-12","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia","volume":"57","author":"Holmes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.japh.2020.02.025_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.japh.2020.02.025_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.japh.2020.02.025_bib9","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.japh.2020.02.025_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s13104-016-2252-7","article-title":"The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis","volume":"9","author":"Tongsai","year":"2016","journal-title":"BMC Res Notes"},{"issue":"24","key":"10.1016\/j.japh.2020.02.025_bib11","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.2146\/ajhp180034","article-title":"Making the change to area under the curve-based vancomycin dosing","volume":"75","author":"Heil","year":"2018","journal-title":"Am J Health Syst Pharm"},{"issue":"Suppl 1","key":"10.1016\/j.japh.2020.02.025_bib12","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/ofid\/ofx162.074","article-title":"The emperor\u2019s new clothes: prospective observational evaluation of the association between the day 2 vancomycin exposure and failure rates among adult hospitalized patients with MRSA bloodstream infections (PROVIDE)","volume":"4","author":"Lodise","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.japh.2020.02.025_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01293-17","article-title":"A\u00a0quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.japh.2020.02.025_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough\u00a0concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.japh.2020.02.025_bib15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/ajhp\/zxz070","article-title":"Readiness to implement vancomycin monitoring based on area under the concentration-time curve: a cross-sectional survey of a national health consortium","volume":"76","author":"Kufel","year":"2019","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"10.1016\/j.japh.2020.02.025_bib16","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"10.1016\/j.japh.2020.02.025_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0924-8579(98)00060-0","article-title":"Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary","volume":"11","author":"Chow","year":"1999","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.japh.2020.02.025_bib18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ijantimicag.2018.08.024","article-title":"Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"52","author":"Mogle","year":"2018","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319120301059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319120301059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:46:48Z","timestamp":1761544008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319120301059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1544319120301059"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2020.02.025","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost comparison of AUC:MIC\u2013 versus trough-based vancomycin monitoring for MRSA bacteremia","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2020.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}